Glycopyrronium (PT001) vs Ipratropium

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline

Glycopyrronium (PT001)

Developed by AstraZeneca

Phase 2/3 in Asthmasmall molecule
Partial signal

NCT03358147 · Phase 2/3 · completed

The study was randomized and quadruple-masked for the placebo comparison, included 1,077 participants, and used placebo and open-label active comparators. Its primary measure was a lung-function surrogate rather than a hard clinical outcome, and although the reported PT001 values were numerically higher than placebo, whether the prespecified primary comparison was statistically significant is not stated.

Next expected readout: May 2029 · NCT07525375 (registry estimate)

Reported efficacy

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412) (unclear)

Result source: NCT03358147

Ipratropium

Marketed by Boehringer Ingelheim

Phase 3 in Asthmasmall molecule
Weak signal

NCT06074185 · Phase 2 · completed

The study was not randomized or blinded and compared patients treated before and after implementation of the bundle rather than using a concurrent controlled trial; the intervention also included dexamethasone and a checklist, so the effect cannot be attributed to ipratropium alone. Although hospital admission is a clinical endpoint, the primary comparison was based on a small and internally inconsistent set of reported participants, with no reported significance analysis, so the result is unclear.

No aligned efficacy figure on record for this race.

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointGlycopyrronium (PT001)Ipratropium
Severe exacerbations, annualised rate—Not reported—Not reported
Trough FEV1, change0.1 vs 0.1±0 vs placebo28.8 μg · wk 24 · n 196NCT03358147
2 other results
  • 0.1 vs 0.1 14.4 μg · wk 24 · n 199 · Phase 2/3 · secondary NCT03358147
  • 0.1 vs 0.1 7.2 μg · wk 24 · n 205 · Phase 2/3 · secondary NCT03358147
—Not reported
ACQ-5, change-0.9 vs -0.9+0.1 vs placebo28.8 μg · wk 24 · n 195NCT03358147
2 other results
  • -0.8 vs -0.9 14.4 μg · wk 24 · n 198 · Phase 2/3 · secondary NCT03358147
  • -1.0 vs -0.9 7.2 μg · wk 24 · n 196 · Phase 2/3 · secondary NCT03358147
—Not reported
OCS dose reduction—Not reported—Not reported

Severe exacerbations, annualised rate

Glycopyrronium (PT001)
—Not reported
Ipratropium
—Not reported

Trough FEV1, change

Glycopyrronium (PT001)
0.1 vs 0.1±0 vs placebo28.8 μg · wk 24 · n 196NCT03358147
2 other results
  • 0.1 vs 0.1 14.4 μg · wk 24 · n 199 · Phase 2/3 · secondary NCT03358147
  • 0.1 vs 0.1 7.2 μg · wk 24 · n 205 · Phase 2/3 · secondary NCT03358147
Ipratropium
—Not reported

ACQ-5, change

Glycopyrronium (PT001)
-0.9 vs -0.9+0.1 vs placebo28.8 μg · wk 24 · n 195NCT03358147
2 other results
  • -0.8 vs -0.9 14.4 μg · wk 24 · n 198 · Phase 2/3 · secondary NCT03358147
  • -1.0 vs -0.9 7.2 μg · wk 24 · n 196 · Phase 2/3 · secondary NCT03358147
Ipratropium
—Not reported

OCS dose reduction

Glycopyrronium (PT001)
—Not reported
Ipratropium
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Glycopyrronium (PT001): 4 of 4 rows · Ipratropium: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGlycopyrronium (PT001)Ipratropium
Dropout rate
14.5%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
16.3%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
14.2%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
—a
NCT06074185 · Phase 2 · combination
show 4 more results
0%
NCT04617015 · Phase 1 · registry result, not featured evidence
0%Arg/Arg Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
5.6%Gly/Gly Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
0%
NCT00583778 · Phase na · registry result, not featured evidence · combination
Discontinued due to AEs
1.3%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
3.8%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
2.9%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
—a
NCT06074185 · Phase 2 · combination
show 4 more results
—
NCT04617015 · Phase 1 · registry result, not featured evidence
—Arg/Arg Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
—Gly/Gly Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
—
NCT00583778 · Phase na · registry result, not featured evidence · combination
Serious AEs
3.8%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
2.9%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
2.5%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0%a
NCT06074185 · Phase 2 · combination
show 4 more results
0%
NCT04617015 · Phase 1 · registry result, not featured evidence
0%Arg/Arg Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
0%Gly/Gly Genotype on Advair (Flutic
NCT00521222 · Phase na · registry result, not featured evidence
0%
NCT00583778 · Phase na · registry result, not featured evidence · combination
Most frequent reported AEs
28.8 μg
upper respiratory tract infection 6% (placebo 8%)
nasopharyngitis 4.7% (placebo 3.4%)
sinusitis 4.3% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
14.4 μg
nasopharyngitis 6.3% (placebo 3.4%)
upper respiratory tract infection 5.8% (placebo 8%)
sinusitis 2.9% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
7.2 μg
nasopharyngitis 7.1% (placebo 3.4%)
upper respiratory tract infection 5.8% (placebo 8%)
sinusitis 1.7% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
a
upper respiratory infection 13.3%
dyspnea 6.7%
right foot fracture 6.7%
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
dyspnea 11.8%
cough 5.9%
pneumonia 5.9%
NCT00521222 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Glycopyrronium (PT001)

FEV1 AUC0-4 0.294 vs 0.24 placebo L @ 24wk28.8 μg
absolute change · L
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.284 vs 0.24 placebo L @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0.308 vs 0.24 placebo L @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
FEV1 Trough 0.142 vs 0.129 placebo L @ 24wk28.8 μg
absolute change · L
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.108 vs 0.129 placebo L @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0.142 vs 0.129 placebo L @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
Moderate to Severe Exacerbation Rate Annualized 0.43 vs 0.55 placebo per year @ 24wk28.8 μg
event rate · per year
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.44 vs 0.55 placebo per year @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0.41 vs 0.55 placebo per year @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
ACQ-7 -0.78 vs -0.8 placebo score @ 24wk28.8 μg
absolute change · score
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
-0.73 vs -0.8 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
-0.9 vs -0.8 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
ACQ-5 -0.87 vs -0.93 placebo score @ 24wk28.8 μg
absolute change · score
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
-0.8 vs -0.93 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
-1.02 vs -0.93 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
AQLQ 0.89 vs 0.96 placebo score @ 24wk28.8 μg
absolute change · score
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.9 vs 0.96 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
1.02 vs 0.96 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3

Ipratropium

PROMIS Asthma Impact Scale 22.5 score @ 1wk
absolute value · score
No placebo or comparator arm
NCT06074185 · Phase 2 · combination
FEV1 10.8% (n=39)
percent change · % of baseline
No placebo or comparator arm
NCT04617015 · Phase 1 · registry result, not featured evidence
show 1 more result
8.9% (n=32)
NCT04617015 · Phase 1 · registry result, not featured evidence
Morning PEF Change L/Min -15.7 vs -5.6 Fluticasone HFA L/min @ 16wk
absolute change · L/min
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
8.4 vs -5.6 Fluticasone HFA L/min @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
FEV1 -0.03 vs -0.12 Fluticasone HFA L @ 16wk
absolute change · L
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-0.08 vs -0.12 Fluticasone HFA L @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
Post-BD FEV1 Change 0.02 vs -0.11 Fluticasone HFA L @ 16wk
absolute change · L
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-0.07 vs -0.11 Fluticasone HFA L @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
FEV1% Predicted -1% (n=15) vs -3.8% (n=13) Fluticasone HFA @ 16wk
absolute change · percentage points
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-2.5% (n=17) vs -3.8% (n=13) Fluticasone HFA @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
Asthma Symptom 0.3 vs 0.4 Fluticasone HFA score @ 16wk
absolute change · score
NCT00521222 · Phase na · registry result, not featured evidence
show 1 more result
-1.2 vs 0.4 Fluticasone HFA score @ 16wk
NCT00521222 · Phase na · registry result, not featured evidence
FEV1 47.5% (n=141) vs 52.5% (n=141) Levalbuterol @ 0wk
responder rate · % of participants
NCT00583778 · Phase na · registry result, not featured evidence · combination · converted to % from 67 Participants as posted
FEV1 Percent Predicted 47% (n=67) vs 45% (n=74) Levalbuterol @ 0wk
absolute change · percentage points
NCT00583778 · Phase na · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrronium (PT001)'s landscape · Ipratropium's landscape